These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dabigatran in clinical practice: Contemporary overview of the evidence. Ageno W, Eikelboom J, Lip GY. Int J Cardiol; 2016 Oct 01; 220():417-28. PubMed ID: 27390965 [Abstract] [Full Text] [Related]
3. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary. Waks JW, Zimetbaum PJ. Expert Rev Cardiovasc Ther; 2013 Nov 01; 11(11):1461-71. PubMed ID: 24147516 [Abstract] [Full Text] [Related]
4. [Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor]. Beliavskaia OO, Vavilova TV. Angiol Sosud Khir; 2014 Nov 01; 20(4):37-41. PubMed ID: 25490355 [Abstract] [Full Text] [Related]
5. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW, Barillari G. J Clin Pharm Ther; 2014 Apr 01; 39(2):118-35. PubMed ID: 24383983 [Abstract] [Full Text] [Related]
6. Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed. Milling TJ, Spyropoulos AC. Am J Med; 2016 Nov 01; 129(11S):S54-S63. PubMed ID: 27569671 [Abstract] [Full Text] [Related]
7. Reversing the anticoagulation effects of dabigatran. Dager WE, Banares L. Hosp Pract (1995); 2017 Apr 01; 45(2):29-38. PubMed ID: 28335637 [Abstract] [Full Text] [Related]
9. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice. Kasmeridis C, Lip GY, Apostolakis S. Hosp Pract (1995); 2013 Feb 01; 41(1):61-70. PubMed ID: 23466968 [Abstract] [Full Text] [Related]
10. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Becattini C, Vedovati MC, Agnelli G. Thromb Res; 2012 Mar 01; 129(3):392-400. PubMed ID: 22264937 [Abstract] [Full Text] [Related]
11. [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran]. Szapary L, Fehér G, Bosnyák E, Deli G, Csécsei P. Ideggyogy Sz; 2013 May 30; 66(5-6):165-74. PubMed ID: 23909016 [Abstract] [Full Text] [Related]
14. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Weitz JI, Pollack CV. Thromb Haemost; 2015 Nov 25; 114(6):1113-26. PubMed ID: 26155974 [Abstract] [Full Text] [Related]
15. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. Fanola CL. Vasc Health Risk Manag; 2015 Nov 25; 11():271-82. PubMed ID: 26064057 [Abstract] [Full Text] [Related]
16. Novel oral anticoagulants in secondary prevention of stroke. Diener HC, Easton JD, Hankey GJ, Hart RG. Best Pract Res Clin Haematol; 2013 Jun 25; 26(2):131-9. PubMed ID: 23953901 [Abstract] [Full Text] [Related]
17. Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study. Verdecchia P, Vedovati MC, Conti S, Giustozzi M, Aita A, Molini G, Angeli F, Turturiello D, Becattini C, Cavallini C, Agnelli G. Expert Opin Drug Saf; 2018 Nov 25; 17(11):1063-1069. PubMed ID: 30260252 [Abstract] [Full Text] [Related]
20. The Impact of Novel Anticoagulants: Should All AF Patients Now Be Anticoagulated? Hammwöhner M, Goette A. J Cardiovasc Pharmacol; 2015 Dec 25; 66(6):530-9. PubMed ID: 26222990 [Abstract] [Full Text] [Related] Page: [Next] [New Search]